Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
CERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $2.59
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.48M
Market Cap
$323.14M
Enterprise Value$345.76M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.88
Next Earnings
May 01, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding185,715,410
10 Day Avg. Volume985,932
30 Day Avg. Volume1,483,880
Standard Deviation0.16
R-Squared0.18
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.91
Price to Cash Flow (P/CF)20.70
P/FCF Ratio25.10
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda-41.17
Forecast
1Y Price Target
$4.00Price Target Upside129.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Cerus News
PremiumCompany Announcements
Cerus Corporation’s 2024 Earnings Call Highlights Growth and Expansion
PremiumCompany Announcements
Cerus Corporation Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Cerus Director Gail Schulze to Step Down
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCERS concluded 2024 with modestly above-expectation 4Q Product Revenues and 2025 guidance capturing Consensus.
Product LaunchThe rollout of IFC continues to gain momentum, with sales driven by more standing orders and deeper utilization within existing accounts.
Bears Say
Regulatory ChallengesThe review of CERS's CE Mark application for INTERCEPT RBC was completed without receiving approval, prompting the company to assess new strategies for regulatory submission.
---
Ownership Overview
15.94% Insiders
15.80% Mutual Funds
42.44% Other Institutional Investors
4.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CERS FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was $1.38 and its highest was $2.58 in the past 12 months.
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is $323.14M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is May 01, 2025 which is in 68 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Feb 20, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.002.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is -0.04.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 185,715,410 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CERS
---
Cerus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (129.89% Upside)
$4.00 (129.89% Upside)
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $32.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.67%
12-Months-Change
Fundamentals
Return on Equity
-38.81%
Trailing 12-Months
Asset Growth
-7.92%
Trailing 12-Months
Company Description
Cerus Corp
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
---
CERS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Cerus Corporation's strong financial performance in 2024, marked by positive adjusted EBITDA and robust revenue growth driven by the IFC and global platelet businesses. However, challenges such as a decline in government contract revenue and increased operating expenses were noted. The overall sentiment is positive given the company's growth trajectory and market expansion efforts.Read More>---
CERS Stock 12 Month Forecast
Average Price Target
$4.00
▲(129.89% Upside)
Technical Analysis
Fate Therapeutics
―
Heron Therapeutics
―
CytomX Therapeutics
―
Anixa Biosciences
―
Allogene Therapeutics
―
Best Analysts Covering CERS
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-7.92%
initiated a buy rating last month
Copying Josh Jennings's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -7.92% per trade.
---